Abstract: An object of the present invention is to provide a method for efficiently producing a peptide compound of high purity at a high yield. It was found that an amino acid can be efficiently loaded on a resin for solid-phase synthesis by bringing an amino acid solution containing a specific solvent into contact with a resin for solid-phase synthesis that has been swollen with a specific solvent, thereby solving such problem.

Abstract: A method for producing a lipid peptide compound represented by formula (3) or a pharmaceutically usable salt thereof, the method comprising: a reaction step of reacting an ester compound of the following Formula (1) with an ?-amino acid compound of the following Formula (2) and a base in a solvent containing a non-polar organic solvent; an extraction step of adding an organic acid to a solution containing a salt of a lipidic peptide prepared through the reaction step and being of the following Formula (3) to thereby neutralize the solution, adding water and an alcohol to the neutralized solution, and subjecting the resultant mixture to phase separation, thereby removing the non-polar organic solvent; and a separation step of removing the lipidic peptide compound of Formula (3) from the solution prepared through the extraction step to the outside of the system.

Abstract: Disclosed is a polypeptide capable of prolonging the lifespan of Caenorhabditis elegans, or pharmaceutically acceptable salts thereof. The polypeptide has an amino acid sequence XKFAA (X: any amino acid, preferably T/A). Further, after one or more amino acids on the foregoing polypeptide sequence are deleted, substituted, or added, the resulting polypeptide or the pharmaceutically acceptable salts thereof still have the anti-aging activity. The polypeptide has the effect of prolonging the lifespan of Caenorhabditis elegans and anti-aging, and also has the function of enhancing the ability of movement behavior, improving the anti-stress ability, and alleviating the decline of movement ability in the aging process.

Abstract: The invention relates to interference peptides as inhibitors of the interactions related to AMPA receptor endocytosis, to peptide compounds comprising said peptides that can be used in medicine, in the field of neurology and psychiatry, in particular for the prevention and therapy of mild cognitive impairment in neurodegenerative diseases or in the prophylaxis of depression and anxiety, as well as to peptidomimetic compounds of interference peptides with a blocking effect on the interaction between AMPA receptor and STEP phosphatase and to a method of inhibiting AMPA receptor endocytosis in neurons, especially in synaptic neurons.

Abstract: The present disclosure relates generally to adeno-associated vims (AAV) capsid polypeptides and encoding nucleic acid molecules. The disclosure also relates to AAV vectors comprising the capsid polypeptides, and nucleic acid vectors (e.g. plasmids) comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells. The disclosure includes AAV capsid polypeptides comprising a peptide modification in variable region 8 (VR VIII), where the peptide modification comprises a 7 amino acid insertion.

Abstract: The present invention provides epitope peptides which are derived from SARS-CoV-2 proteins and have the ability to induce cytotoxic T cells. The present invention also provides polynucleotides encoding the peptides, antigen-presenting cells that present the peptides, and cytotoxic T cells that target the peptides, and methods of inducing the antigen-presenting cells or CTLs. The present invention further provides compositions and pharmaceutical compositions containing them as active ingredients. Moreover, the present invention provides methods of treating and/or preventing coronavirus infectious diseases, and/or methods of suppressing the aggravation of coronavirus infectious diseases by using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells, or pharmaceutical compositions of the present invention. The present invention also provides methods of inducing an immune response against coronavirus infection.

Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

Abstract: The present invention relates to modified hMPV F proteins stabilized in the pre-fusion conformation as vaccine candidates.

Abstract: Disclosed are a partial peptide of cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 (CAP), consisting of an amino acid sequence of the conserved region of CAP, the peptide having at least one effect selected from the following effects: a plant stem cell-inducing effect, a plant environmental stress tolerance-enhancing effect, a plant pest resistance-inducing effect, a germination-promoting effect, a plant transformation efficiency-enhancing effect, and a plant growth-promoting effect; and a plant stem cell inducer, an environmental stress enhancer, a plant pest resistance inducer, a germination promoter, a transformation efficiency enhancer, and a plant growth promoter, all of which comprise the peptide.

Abstract: The present disclosure relates to the field of biomedicine, in particular to the use of MCM8-cGAS-STING-IFN-I signal pathway as a disease target, including the use in the preparation of an animal model of a disease or the preparation of a product for the diagnosis, prevention, or treatment of a disease. In particular, the present disclosure comprises the use of a reagent for quantitatively detecting the gene expression or protein expression or protein activity of MCM8 in the preparation of a product for the diagnosis of a disease caused by dysfunctional mitophagy or caused by abnormal activation of cGAS-STING-IFN-I signaling pathway.

Abstract: The present disclosure provides, among other things, methods and compositions useful for induction of cell death. The present disclosure provides translatable nucleic acids encoding constitutively active payloads capable of inducing cell death. Payloads of the present disclosure are particularly useful in induction of immunogenic cell death.

Abstract: Provided herein are antimicrobial peptides, as well as methods of treating a microbial infection, methods of treating inflammation, and methods of reducing biofilm formation, using the disclosed antimicrobial peptides.

Abstract: The present invention relates to a novel peptide capable of inhibiting TGF-? signaling and the use thereof. The peptide of the present invention is capable of inhibiting the TGF-?-induced signaling pathway or the expression of TGF-?, and thus can treat or prevent various diseases caused by TGF-? signaling, and furthermore, can effectively inhibit tumorigenesis processes such as TGF-?-signaling induced tumor growth and metastasis.

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

Abstract: The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.

Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Abstract: The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.

Abstract: One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.

Abstract: Disclosed are polypeptides which are pramlintide analogues and uses thereof. In particular, the present invention relates to polypeptides of SEQ ID NO 2 which are pramlintide analogues conjugated to half-life extending moieties such as albumin binding moieties and uses thereof.

Abstract: The present invention provides for novel synthetic approach of solid phase synthesis of peptides with C-terminal Aspartic acid by anchoring the side chain carboxylic group of aspartic acid to the solid support to avoid the formation of various impurities and thus resulting in higher yield and ease the purification process. The present invention further provides the usage of free amino acids and reducing agents as antioxidants in the cleavage cocktail to negate the formation of oxidative impurities formed during the global cleavage and isolation of the peptide from solid support.

Abstract: The present invention relates to compositions comprising GLP-2 protein or variants thereof linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of GLP-2 related conditions.

Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO:1 to SEQ ID NO:113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.

Abstract: The present disclosure provides T-cell modulatory polypeptides (TMPs) that comprise an immunomodulatory polypeptide, class I HLA polypeptides (a class I HLA heavy chain polypeptide and a ?2 microglobulin polypeptide), and a peptide that presents an epitope to a T-cell receptor. A TMP of the present disclosure is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

Abstract: The present disclosure provides T-cell modulatory polypeptides (TMPs) that comprise a MOD, class I HLA polypeptides (a class I HLA heavy chain polypeptide and a ?2 microglobulin polypeptide), and a KRAS peptide (e.g., a KRAS peptide comprising a cancer-associated mutation) that presents an epitope to a T-cell receptor. A TMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

Abstract: The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

Abstract: A class of lactam-modified polypeptide compounds and the use thereof in the preparation of a drug for treating related diseases.

Abstract: The present disclosure relates to a mutant neuroserpin protein or portion thereof, to a nucleic acid comprising nucleotide sequence which encodes a mutant neuroserpin protein or portion thereof, and to use of the nucleic acid or mutant neuroserpin protein or portion thereof for treating glaucoma and other disorders associated with elevated plasmin activity.

Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.

Abstract: The invention provides a set of novel Single domain VHH antibodies against SARS-CoV-2 (SEQ ID N? 1-6) and their use to detect and neutralize the wild type virus.

Abstract: Disclosed are a fully human broad-spectrum neutralizing antibody against coronavirus, and the use thereof. Specifically disclosed are a fully human monoclonal antibody against an S2 region of coronavirus S protein, a nucleic acid sequence encoding the antibody, and a preparation method therefor. The antibody can effectively bind to and neutralize a variety of coronaviruses in a broad spectrum manner, and can be used for preventing and treating diseases related to coronavirus infection, such as SARS-CoV-2. Further disclosed is the potential use thereof in vaccine design.

Abstract: The invention provides anti-Tau antibodies and methods of using the same.

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.

Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.

Abstract: Provided are an anti-VEGF hexameric antibody, and a composition including the hexameric antibody.

Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.

Abstract: Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specifically binding to a); f) an antibody specifically binding to b); g) an antibody specifically binding to c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g). Pharmaceutical compositions and processes for making and using the compositions are also disclosed.

Abstract: The present disclosure provides monoclonal antibodies (e.g., anti-TNF? antibodies) having Fab sialylation, and, in some aspects, Fab sialylation in combination with an afucosylated Fc. Such antibodies having improved immunogenicity profiles and related advantages. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such monoclonal antibodies are useful for treating and preventing various diseases.

Abstract: The present invention provides for recombinant antibodies having the features of ruminant early colostrum antibodies that impart resistance to proteases and intestinal digestion. It is a feature of the present invention that when administered to animals including humans, pharmaceutical compositions comprising the novel recombinant antibodies of the present invention, advantageously exhibit resistance to proteases and intestinal digestion. Thus, pharmaceutical compositions of the recombinant antibodies of the invention may be used to deliver antibody therapeutics particularly by oral delivery to the gastrointestinal tract when oral delivery is advantageous.

Abstract: Disclosed herein are compositions comprising ionic liquids and the use thereof for treating conditions or diseases in a subject.

Abstract: Provided herein are methods of preventing or reducing the incidence of primary graft dysfunction in a subject.

Abstract: The present invention provides, inter alia, antibodies that modulate binding between Lrp5 and WISE or Lrp6 and WISE, but do not modulate binding between Lrp4 and WISE. Also provided are pharmaceutical compositions and kits containing such antibodies. Further provided are methods for preventing WISE binding to Lrp5 or Lrp6, but not WISE binding to Lrp4.

Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Abstract: A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition includes a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.

Abstract: The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1-54, which may be encoded by SEQ ID NOS: 55-110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses.

Abstract: The present disclosure relates to field of immune checkpoints in onco-immunology and their identification as potential targets for the treatment of cancer patients: it provides VHHs (Single-domain antibody fragments, also known as ‘heavy-chain variable domains’ or ‘nanobodies’) to detect and quantify in a non-invasive way the immune checkpoint LAG-3.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.